INT72789

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 29
Total Number 30
Disease Relevance 12.36
Pain Relevance 9.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Cpa1) extracellular space (Cpa1) extracellular region (Cpa1)
Anatomy Link Frequency
CPA 30
Cpa1 (Mus musculus)
Pain Link Frequency Relevance Heat
narcan 72 99.84 Very High Very High Very High
opiate 7 99.80 Very High Very High Very High
withdrawal 28 99.64 Very High Very High Very High
Morphine 54 99.08 Very High Very High Very High
agonist 59 98.88 Very High Very High Very High
Pain 294 98.50 Very High Very High Very High
Enkephalin 3 97.92 Very High Very High Very High
antagonist 52 97.60 Very High Very High Very High
mu opioid receptor 6 97.32 Very High Very High Very High
Endogenous opioid 3 96.80 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 2436 100.00 Very High Very High Very High
Pain 287 98.50 Very High Very High Very High
Colorectal Cancer 448 98.32 Very High Very High Very High
Disease 169 96.80 Very High Very High Very High
Aggression 8 96.28 Very High Very High Very High
Hyperalgesia 2 93.60 High High
Residual Neoplasm 140 92.60 High High
Apoptosis 62 91.20 High High
Stress 106 88.24 High High
Hematologic Neoplasms 14 87.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While all three drugs produced CPA, only naloxone CPA was enhanced by morphine given 20 h prior to each naloxone injection.
Gene_expression (produced) of CPA in CPA associated with narcan and morphine
1) Confidence 0.50 Published 2006 Journal Neuropsychopharmacology Section Abstract Doc Link 15956992 Disease Relevance 0 Pain Relevance 1.55
Naloxone administration produces a robust conditioned place aversion (CPA) in opiate-naive rodents by blocking the action of enkephalins at mu opioid receptors.
Gene_expression (produces) of CPA in CPA associated with mu opioid receptor, narcan, enkephalin and opiate
2) Confidence 0.50 Published 2006 Journal Neuropsychopharmacology Section Abstract Doc Link 15956992 Disease Relevance 0 Pain Relevance 0.84
The CPA produced by naloxone was compared with that produced by the neutral antagonists 6-alpha- and 6-beta-naloxol in mice with and without prior morphine exposure.
Gene_expression (produced) of CPA in CPA associated with antagonist, narcan and morphine
3) Confidence 0.50 Published 2006 Journal Neuropsychopharmacology Section Abstract Doc Link 15956992 Disease Relevance 0 Pain Relevance 1.39
As expected, ethanol produced a robust conditioned place aversion (CPA).
Gene_expression (produced) of CPA in CPA
4) Confidence 0.49 Published 1997 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 9408203 Disease Relevance 0 Pain Relevance 0.48
The CPA produced by coadministration of naloxone and ethanol was attributed to naloxone's effects on the neural processes underlying ethanol's unconditioned aversive effects, or to other nonspecific effects on ethanol's motivational properties.
Gene_expression (produced) of CPA in CPA associated with narcan
5) Confidence 0.49 Published 1997 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 9408203 Disease Relevance 0 Pain Relevance 0.54
However, naloxone had no effect on expression of CPA.
Gene_expression (expression) of CPA in CPA associated with narcan
6) Confidence 0.49 Published 1997 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 9408203 Disease Relevance 0 Pain Relevance 0.52
Testing for the expression of CPP or CPA was conducted on day 10 using the pretest procedure.
Gene_expression (expression) of CPA in CPA
7) Confidence 0.27 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2516177 Disease Relevance 0 Pain Relevance 0.03
Interestingly, ALDH1 staining in CPA-treated tumors appeared to localize to the apical surface, where it may be hypothesized to intercept CPA metabolites as they enter the cell.
Gene_expression (metabolites) of CPA in CPA associated with cancer
8) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.79 Pain Relevance 0
Furthermore, initiation of tumorigenesis with ALDH1A1- versus Luciferase-targeted shRNA containing cells was identical, demonstrating that ALDH1 enzymatic activity is not requisite in the absence of CPA exposure.
Gene_expression (exposure) of CPA in CPA
9) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.72 Pain Relevance 0
ALDH1A1, MYC, and MYB are enriched in residual TG cells post CPA therapy
Gene_expression (therapy) of CPA in CPA
10) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.36 Pain Relevance 0
Intracellular levels of ALDH1 and nuclear c-Myc, for example, were more prevalent in CPA-treated tumors (Figure 4C).
Gene_expression (levels) of CPA in CPA associated with cancer
11) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.81 Pain Relevance 0
Following the isolation of TG versus NTG populations from both vehicle- and CPA-treated UM-C4 tumors with >99% purity, expression of numerous genes with suggested ties to colorectal cancer was determined by Taqman™ qRT-PCR.
Gene_expression (expression) of CPA in CPA associated with colorectal cancer and cancer
12) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.44 Pain Relevance 0
CPA resistance is specific to cells with high ALDH1 activity
Gene_expression (resistance) of CPA in CPA
13) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.92 Pain Relevance 0
Like the observed phenotypic increase in CD166+ cells (Figures 1E, S1B & S1C), the ALDH+ subpopulation of ESA+CD44+ cells was consistently higher in CPA- versus vehicle-treated control mice (67.6±6.3% versus 56.8±6.8%, respectively; n?
Gene_expression (higher) of CPA in CPA
14) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.42 Pain Relevance 0
Interestingly, ALDH1 staining in CPA-treated tumors appeared to localize to the apical surface, where it may be hypothesized to intercept CPA metabolites as they enter the cell.
Gene_expression (staining) of CPA in CPA associated with cancer
15) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.75 Pain Relevance 0
ALDH1, in particular, may play a major role in CPA resistance, as it's Km for CPA is ?
Gene_expression (is) of CPA in CPA
16) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.52 Pain Relevance 0
Finally, gene expression differences in CPA- versus vehicle-treated control tumors were further correlated with protein expression by immunofluorescence and IHC.
Gene_expression (expression) of CPA in CPA associated with cancer
17) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.78 Pain Relevance 0
Resistance to CPA has been suggested to result from high cytoplasmic aldehyde dehydrogenase (ALDH) enzyme activity: particularly that of ALDH1 and ALDH3 [20], [21], which oxidize and inactivate the bioactive metabolic byproduct of CPA, aldophosphamide/4-hydroxycyclophosphamide (4-HC) [22], [23].
Gene_expression (byproduct) of CPA in CPA
18) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.49 Pain Relevance 0
ALDH1, in particular, may play a major role in CPA resistance, as it's Km for CPA is ?
Gene_expression (resistance) of CPA in CPA
19) Confidence 0.21 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2413402 Disease Relevance 0.52 Pain Relevance 0
2.53; p<0.05), and CPA (F (4,84)?
Gene_expression (2.53) of CPA in CPA
20) Confidence 0.20 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2516177 Disease Relevance 0.42 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox